Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases. The company strives to transform and simplify care for people with life-threatening illnesses around the world. © 1996-2021 Gilead Sciences, Inc. All rights reserved. “Throughout my career, I have been focused on translating scientific discoveries into the development of potential new … Novo Nordisk is a healthcare company that designs and manufactures pharmaceutical products. Gilead Sciences annual research and development expenses for 2020 were … See if you qualify! https://www.businesswire.com/news/home/20200930005527/en/, Douglas Maffei, PhD, Investors Gilead Sciences, Inc. is a research-based biopharmaceutical company founded in 1987. Export Data Save Image Print Image For advanced charting, view our full-featured Fundamental Chart. Sr. Research Scientist I, Formulation Process Development United States - California - Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients … (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in … +1 (650) 522-2739, Rhiannon Bid, Media (Europe) Gilead Sciences (GILD) has been actively researching new drugs for HIV and HCV. Clinical Trials Transparency & Data Sharing Policy, Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer, Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19, Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program, Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program, Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services, Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD. Gilead will present 13 studies from the company’s HIV research and development programs in addition to supporting several other independent studies at the conference, which, along with its community-focused programs, reflect Gilead’s ongoing focus and commitment to advancing scientific discovery and supporting the development and delivery of practical solutions that can help improve care for all people affected by HIV. Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Welcome back. Together we deliver life-saving therapies to patients in need. Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Biktarvy. +44 (0) 7824 530 487. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead will have the right to appoint two individuals to Arcus’s Board of Directors upon closing of the transaction. Poster 032: Persistence of guideline-recommended antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the U.S. View job description, responsibilities and qualifications. Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020 -- New Findings on Biktarvy^® to ^ Include Long-term Switch Studies as … Some of the content on this page is not intended for users outside the US. Gilead will present 13 studies from the company’s HIV research and development programs in addition to supporting several other independent studies at … U.S. full Prescribing Information for Biktarvy, including BOXED WARNING, is available at www.gilead.com. With the commitment and drive you bring to the workplace every day, you will be part of a team that is changing the world and helping millions of people live … Gilead’s $200 million equity investment will be at a price per share of $33.54. Twelve-month data and a preliminary, descriptive analysis of patient-reported outcomes will also be presented from the global BICSTaR study, a real-world, observational study evaluating the effectiveness, safety, and tolerability of Biktarvyin treatment-naïve and treatment-experienced people living with HIV. Please see below for U.S. Gilead has operations in more than 35 countries worldwide, with … See if you qualify! About Gilead Sciences. Easy 1-Click Apply (GILEAD SCIENCES, INC.) Senior Director, Biostatistics - Statistical Research and Software Development job in Seattle, WA. Catalent. Gilead S… Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead is committed to supporting the global health community to quickly and effectively respond to serious and life-threatening viral outbreaks worldwide. It had a 150-employee R&D facility in Durham at one time, but it closed that facility in 2010 and consolidated its research at its Foster City headquarters. To that end, we are contributing our antiviral expertise and resources to help investigate potential treatments for patients with COVID-19. Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Executive Director Quality Development and Commercial QA United States - California - Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. In addition, the role will include management and leadership of one or more Medical Affairs research studies. Contact. The role will support the development, implementation, and management of IEP generation, as well as Real World Data/Evidence (RWD/RWE) working groups across all Gilead therapeutic areas (TAs). Gilead Sciences Research and Development Expense (TTM): 11.15B for Sept. 30, 2020. A revolutionary approach to cancer therapy. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Some content on this site is not intended for people outside the United States. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Single tablet regimens for HIV. Learn More About Our Research Pipeline Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. In addition, it is possible that Gilead may make a strategic decision to discontinue development of lenacapavir and as a result, lenacapavir may never be successfully commercialized. Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Data on the impact of the COVID-19 pandemic on HIV clinics and services in Greece will also be presented. Together we deliver life-saving therapies to patients in need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Easy 1-Click Apply (GILEAD SCIENCES, INC.) Senior Director, Biostatistics - Statistical Research and Software Development job in Seattle, WA. The company strives to transform and simplify care for people with life-threatening illnesses around the world. The company's product development efforts cover a wide range of medical conditions, including HIV/AIDS, liver diseases, hematology/oncology, and inflammation/respiratory diseases. The company intend to continue committing significant resources to internal R&D opportunities and external business development activity. Research Scientist, Process Development United States - California - Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead has a history in N.C. We do this through internal research and development, as well as through collaborations with academic and industry partners. Oral 324: Lenacapavir resistance analysis in a Phase 1b clinical proof-of-concept study. View job description, responsibilities and qualifications. AELIX Therapeutics S.L. About Gilead Sciences . Together we deliver life-saving therapies to patients in need. Sr. Research Scientist I - Formulation & Process Development Gilead Sciences, Inc. is a research-based biopharmaceutical company founded in 1987. View this and more full-time & part-time jobs in San mateo, CA on Snagajob. Biktarvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. View source version on businesswire.com: In addition to HIV and hepatitis C … Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the HIV Glasgow 2020 conference, taking place virtually from October 5-8. Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Gilead Sciences spent over five billion U.S. dollars on research and development in 2020. Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. -- New Findings on Biktarvy® toInclude Long-term Switch Studies as well as Real-World Data and Patient Reported Outcomes from the BICSTaR Study --, -- Data Evaluating Drug Resistance in People Receiving Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor, as Part of a Long-acting HIV Treatment Regimen to be Presented --. “Gilead has outstanding research and clinical development programs across Virology, Immunology and Oncology, and I am tremendously excited to be joining an organization with such a deep and talented scientific core,” commented Dr. Martin. Our worldwide staff is a close … Browse... View Full Chart Research and Development Expense (TTM) Chart . At the end of 3Q15, Gilead Sciences (GILD) has a strong late-stage research and development (or R&D) pipeline. Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. In the U.S., the use of Biktarvy in individuals with a history of treatment failure or known resistance to the components of Biktarvy is investigational, and the safety and efficacy of Biktarvy for this use have not been established. The results of this large-scale study are expected to underline the importance of real-world evidence and patient-reported outcomes in understanding the impact on mental health component scores, health-related quality of life (HRQoL) and treatment satisfaction of people living with HIV, which could inform treatment strategies for these groups. In addition to HIV and hepatitis C … Biopharmaceutical company Gilead Sciences reported total revenues of approximately 24.7 billion U.S. dollars in 2020, representing a year-on-year increase of over two billion U.S. dollars. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Historical Research and Development Expense (TTM) Data. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Director, Clinical Research (MD) - Oncology/Hematology Early Development United States - California - Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Gilead Sciences (GILD) has been actively researching new drugs for HIV and HCV. In an effort to better understand the barriers that can influence engagement in HIV care at individual, systemic and community levels, Gilead will also convene discussions with the HIV community. View 4,000+ financial data types. This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical trials involving Biktarvy and lenacapavir, and the possibility that we are unable to complete one or more of such trials in the currently anticipated timelines or at all. Select Gilead HIV clinical development program data to be presented at Glasgow 2020: For more information, including a complete list of abstract titles at the meeting, please visit: http://www.hivglasgow.org/wp-content/uploads/2020/09/Poster-Listing_16-September.pdf. Research Scientist - Formulation & Process Development United States - California - Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Posting id: 623929960. U.S. View job description, responsibilities and qualifications. Gilead spends about 23% of its total revenues on research and development. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas … For more than 30 years, Gilead’s research program has achieved advancements that were once thought impossible. View job description, responsibilities and qualifications. As we bring new products into clinical development, our goal remains the same – to discover, develop and commercialize therapeutics that transform care for people around the world. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP®, Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines, http://www.hivglasgow.org/wp-content/uploads/2020/09/Poster-Listing_16-September.pdf, https://www.businesswire.com/news/home/20200930005527/en/, Poster 036: Long-term follow-up after a switch to bictegravir/emtricitabine/tenofovir alafenamide, from a boosted protease inhibitor-based regimen, Poster 123: Sustained viral suppression after switch to bictegravir/emtricitabine/tenofovir alafenamide among clinical trial participants with pre-existing M184V/I, Poster 038: Switching to bictegravir/emtricitabine/tenofovir alafenamide in adults aged >65 or older: week 72 results from an international, Phase 3b, open-label trial, Poster 046: Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the global BICSTaR study, Poster 053: Patient-reported outcomes after one year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV: the BICSTaR cohort, Poster 124: Bictegravir/emtricitabine/tenofovir alafenamide shows high efficacy in clinical study participants infected with HIV-1 subtype F, Poster 029: Impact of adherence on viral suppression with bictegravir and dolutegravir containing triple therapy in clinical practice, Poster 100: The clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide – real-world data from the German IQVIA prescription database. Terms of the Equity Investment. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. “As the needs of the HIV community evolve, we must also evolve our efforts to end the HIV epidemic through our scientific innovation and community support,” said Diana Brainard, MD, Senior Vice President and Virology Therapeutic Area Head, Gilead Sciences. The company strives to transform and simplify care for people with life-threatening illnesses around the world. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Today, it’s estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Indication and Important Safety Information, including Boxed Warning, for Biktarvy. Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. In depth view into Gilead Sciences Research and Development Expense (TTM) including historical data from 1992, charts, stats and industry comps. The company strives to transform and simplify care for people with life-threatening illnesses around the world. © 1996-2021 Gilead Sciences, Inc. All rights reserved. Connect with experts in your field. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Research and Development. Additional treatment research presented at the meeting includes findings from a Phase 1b proof-of-concept study evaluating Gilead’s investigational, novel inhibitor of HIV-1 capsid function, lenacapavir, which is being developed as a component of a long-acting regimen in combination with other antiretroviral agents. “We constantly seek to understand the evolving unmet needs among persons living with HIV, and we are pleased to present new switch data for Biktarvy, as well as real-world findings and patient-reported outcomes from a treatment perspective, and new data on our first-in-class investigational long-acting injectable lenacapavir, which may represent a novel approach to HIV treatment.”. Gilead will provide $40 million in research support and basic science infrastructure development during the initial four-year period, and will provide a total of up to $100 million over 10 years should the collaboration be extended through that timeframe. Catalent Pharma Solutions is a company providing integrated services, drug delivery technologies, and … Gilead will further provide ongoing research and development support of up to $400 million over the collaboration term. Our research and development programs currently focus on potential treatments in HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Gilead spends about 23% of its total revenues on research and development. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The compan Gilead’s research and development program is focused on what’s next. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Lenacapavir is an investigational compound and is not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority and its safety and efficacy are not yet known. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. See if you qualify! All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. The company strives to transform and simplify care for people … ... (FQ) under early clinical development. The statistic illustrates Gilead Sciences' spending on research and development from 2008 to 2020. The company's R&D philosophy and strategy are to develop best-in-class drugs that improve safety or efficacy for unmet medical needs. At the end of 3Q15, Gilead Sciences (GILD) has a strong late-stage research and development (or R&D) pipeline. Research Scientist - Formulation & Process Development Gilead Sciences, Inc. is a research-based biopharmaceutical company founded in 1987. Gilead Sciences, Inc. today announced its upcoming contributions to the HIV Glasgow 2020 conference, taking place virtually from October 5-8. Learn More About Our Research Pipeline With the commitment and drive you bring to the workplace every day, you will be part of a team that is changing the world and helping millions of people live healthier, more fulfilling lives. Important Safety Information for Biktarvy, BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. For more than 30 years, Gilead’s research program has achieved advancements that were once thought impossible. See if you qualify! At the end of 3Q15, Gilead Sciences has a strong late-stage research and development (or R&D) pipeline. As we bring new products into clinical development, our goal remains the same – to discover, develop and commercialize therapeutics that transform care for people around the world. In depth view into Gilead Sciences Research and Development Expense (Quarterly) including historical data from 1992, charts, stats and industry comps. Clinical Trials Transparency & Data Sharing Policy, Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer, Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19, Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program, Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program, Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services, Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD.